SOLVMedical technology and dental products
Solventum
- Price
- $84.51
- Discount category
- Pricey
- Analysts
- Leaning bullish
- Next earnings
- Feb 25 · · estimated
- Pick status
- Research only
In short
- Thesis
- The market doubts that Solventum can grow faster after its split from 3M while it carries debt and lawsuits, and steady growth with a separation of Health Information Systems that adds value can lift its value.
- Gap
- Can close. The Q4 2026 report, expected in late February 2027, and the planned separation of Health Information Systems show whether growth and margins rise after the split from 3M.
Company guidance: 2026 organic sales growth toward the high end of +2.5% to +3.0%; adjusted EPS $7.20 to $7.30; free cash flow $200 to $300 million (, Q3 2026 results release (8-K))
Price history
About
Solventum Corporation (Solventum) is based in Eagan, Minnesota. 3M spun it off on April 1, 2024. It makes and sells health care products in three segments: MedSurg, which includes Advanced Wound Care and Infection Prevention and Surgical Solutions, Dental Solutions and Health Information Systems. It sold its Purification and Filtration business to Thermo Fisher Scientific on September 1, 2025, and it bought Acera Surgical in December 2025.
Net sales were $1,949 million in Q3 2026 and $6,165 million for nine months. The common stock trades on the NYSE in US dollars. Solventum files 10-K and 10-Q reports.
Thesis
The price of Solventum depends on whether it can grow faster and widen its margins after its separation from 3M. In Q3 2026 organic sales fell 2.8%, because customers placed advance orders in Q2 before the cutover to a new ERP system, and Solventum has now exited about 90% of its transition service agreements with 3M. For nine months, organic sales grew 2.9% and the adjusted operating income margin rose to 22.8% from 20.7%. Solventum carries $5.1 billion of debt, its 10-Q describes about 8,400 lawsuits about the Bair Hugger warming system, and it plans to separate its Health Information Systems business, which had an operating margin of 40.3% for nine months.
For the price to hold or rise, four things must be true. Organic sales growth must reach the high end of the 2026 range of 2.5% to 3.0% and rise in 2027 when the effect of the advance orders ends. The margin must keep rising after the exit from the 3M agreements. Free cash flow must grow from the $200 million to $300 million that Solventum expects for 2026, so that debt can fall.
The separation of Health Information Systems must give value to shareholders. The Q4 2026 report, expected in late February 2027, is the next test.
Checkpoints
- Feb 25, 2027 · est.PendingQ4 2026 results and 2027 guidanceAdjusted earnings per share for 2026 are in the range of $7.20 to $7.30 and the 2027 guidance shows higher organic growth, and this passes; results below the range fail.
- 2027 · est.PendingSeparation of Health Information SystemsSolventum announces a sale or spin-off of Health Information Systems with terms that lower debt or return value to shareholders, and this passes; a stopped or long delayed separation fails.
Recent events
- November 5, 2026Solventum reported Q3 2026 results. Net sales fell 7.0% to $1,949 million and organic sales fell 2.8%, because of the reversal of advance orders from Q2. Adjusted diluted earnings per share were $1.45 and the GAAP loss per share was $0.07. Solventum raised its 2026 guidance for adjusted earnings per share to $7.20 to $7.30 and expects organic sales growth near the high end of 2.5% to 3.0%.
- September 30, 2026In the first nine months of 2026, Solventum repurchased 5.3 million shares for about $403 million under the $1 billion program that the board approved in November 2025.
- August 5, 2026Solventum announced that it intends to separate its Health Information Systems business. It is evaluating a range of separation pathways.
Show 2 older eventsHide older events
- July 16, 2026The board appointed Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer from August 10, 2026. He replaced Mary Wilcox, who retired.
- June 30, 2026In Q2 2026, Solventum received $55 million from an insurance policy that covers litigation costs that it paid before.
Latest news and filings
- Last earnings
- November 5, 2026 (8-K on sec.gov)
- Next earnings
- Expected about February 25, 2027. The company has not confirmed the date.
- 10-QQuarterly report for the period ended Sep 30, 2026Filed solv-20260930
- 8-KEarnings releaseFiled Press release and exhibits
- 10-QQuarterly report for the period ended Jun 30, 2026Filed solv-20260630
- 8-KEarnings releaseFiled Press release and exhibits
- 8-KInvestor disclosure and Other company newsFiled solv-20260805
- 8-KChange of directors or officersFiled solv-20260716
- 8-KOther company newsFiled solv-20260602
- 8-KChange of directors or officersFiled solv-20260521
- 8-KShareholder vote resultsFiled solv-20260515
- 10-QQuarterly report for the period ended Mar 31, 2026Filed solv-20260331
Risks
- Product lawsuits can cost money. The 10-Q describes about 8,400 lawsuits in the United States, with 3M as a named defendant, that say the Bair Hugger patient warming system caused surgical site infections.
- Debt is high. Total debt was $5,068 million at September 30, 2026, and $507 million of it is due within one year.
- The separation from 3M and the planned separation of Health Information Systems cost money and management time. Restructuring and separation costs helped lower the GAAP operating income margin to 3.5% in Q3 2026.
- Tariffs and inflation can lower margins. The 10-Q says that the US imposed new tariffs under other laws after the Supreme Court decision on IEEPA tariffs.
- Free cash flow is low. It was negative $32 million for nine months of 2026, and Solventum expects $200 million to $300 million for the year.
Key statistics
- Market cap
- $14B
- Shares of Oct 31, 2026
- P/E (trailing)
- 95.0
- Price of Nov 20, 2026
- EPS (trailing)
- $0.89
- 12 months to Sep 30, 2026
- 52-week range
- $62.38 – $94.16
- To Nov 12, 2026
- Average volume
- 1.1M
- 3 months, to Nov 12, 2026
Check the numbers:ExchangeGoogle FinanceYahoo FinanceSEC filings
Balance sheet
- Cash
- $451M
- Debt
- $5.1B
- Net debt
- $4.6B
- Credit line
- $2.0B
- undrawn
Cash against debt
debt covered by cashnet debt $4.6B
When the debt is due
The last debt is due in 2064.
At September 30, 2026, Solventum had cash and cash equivalents of $451 million. Total debt was $5,068 million at carrying value: senior notes due from 2027 to 2064, $110 million on a three-year term loan and $48 million of other borrowings. Debt due within one year was $507 million, which includes $349 million of 5.45% notes due 2027. The $2.0 billion revolving credit facility, which expires in 2029, had no borrowings, and there was no commercial paper. Finance leases of $206 million and pension and postretirement benefits of $355 million are not in the debt tile. Operating cash flow was $215 million for nine months and capital spending was $247 million. Total equity was $4,805 million.
Dividends
Solventum does not pay a dividend.
Source: company filings and market data, read on November 12, 2026.
Questions about Solventum
What does Solventum do?
Solventum Corporation (Solventum) is based in Eagan, Minnesota. 3M spun it off on April 1, 2024. Its market cap is $14B at the current price of $84.51.
When does Solventum report earnings next?
This is an estimate: Solventum may report on February 25, 2027. It last reported results on November 5, 2026.
Is Solventum stock below its intrinsic value?
Solventum stock is pricey. This is general information, not advice.
What changed recently at Solventum?
The latest update is from November 5, 2026. Solventum reported Q3 2026 results.
What are the main risks for Solventum?
Product lawsuits can cost money. Debt is high. The separation from 3M and the planned separation of Health Information Systems cost money and management time.
How much debt and cash does Solventum have?
At September 30, 2026, Solventum had $5.1B of debt and $451M of cash.
Does Solventum pay a dividend?
No. Solventum does not pay a dividend.
Valuation against peers
| Company | P/E, last 4 quarters | EV/EBITDA, last year | Free cash flow yield, last year | 10-year average P/E |
|---|---|---|---|---|
| SOLVSolventum | 95.0x | n/a | -0.1% | n/a |
| MDLNMedline | n/a | 17.9x | 2.7% | n/a |
| BABoeing | 16.1x | 23.8x | -1.5% | n/a |
| STESTERIS | 32.3x | 16.3x | 3.9% | 44.0x |
| UNPUnion Pacific | 22.4x | n/a | 3.2% | n/a |
| Peer median | 22.4x | 17.9x | 2.9% | n/a |
- SOLV trades at 95.0x earnings, 324% above the peer median of 22.4x.
- Its free cash flow yield is -0.1%, 3.0 points below the peer median of 2.9%.
The peers are the companies on this site most like SOLV. The multiples come from company filings and today's price. There are no analyst forecasts: they all look back. EV/EBITDA is left out for banks, insurers and real estate companies. This is general information, not advice.
Similar companies
- MDLNMedlineShares: Tariffs and trade, Regulation and courts, High debt
- Intrinsic value
- Below intrinsic value
- Gap
- Can close
- BABoeingShares: High debt, Regulation and courts, Tariffs and trade
- Intrinsic value
- Well below intrinsic value
- Gap
- Slow
- STESTERISShares: High debt, Tariffs and trade, Regulation and courts
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
- UNPUnion PacificShares: Regulation and courts, Tariffs and trade, High debt
- Intrinsic value
- Far above intrinsic value
- Gap
- Can close
- IFFInternational Flavors & FragrancesShares: High debt, Regulation and courts, Tariffs and trade
- Intrinsic value
- Below intrinsic value
- Gap
- Can close
Loading your notes…
Read it all? Star SOLV or pass, then go on to the next one.